You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體-B(03681.HK)發售價每股7.60港元 預期11月12日上市
格隆匯 11-11 06:53

格隆匯11月11日丨中國抗體-B(03681.HK)公佈,全球發售約1.82億股,其中香港發售1821.3萬股,國際發售約1.64億股;發售價每股7.60港元;每手300股;預期11月12日上市。

公告顯示,香港公開發售獲大幅超額認購,相當於根據香港公開發售初步可供認購的香港發售股份總數約12.87倍。國際發售獲超額認購約1.38倍。

基石投資者方面,白藥集團及瑞捷軟件科技(香港)有限公司各自已認購5159.94萬股發售股份及1031.97萬股發售股份,總計6191.91萬股發售股份,合共佔(i)緊隨全球發售完成後公司已發行股本約6.15%;及(ii)全球發售的發售股份數目約34.00%。

公告稱,所得款項淨額估計約為12.86億港元。其中,約50.00%用於研發及商業化集團在研藥物;約40.00%用於建設集團的蘇州生產基地;約10.00%用作營運資金、擴大內部能力及其他一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account